Filing Flows › Gossamer Bio (GOSS) › Q4 2025
Gossamer Bio (GOSS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 17, 2026
Gossamer Bio (GOSS) reported revenue of $13.8M for the fourth quarter 2025 (Q4 2025), +47% from a year earlier and +4% from the quarter before. Operating margin was -333.6%, net loss $47.2M (342.3% of revenue).
Gossamer Bio, Q4 2025: revenue $13.8M (+47% year over year), operating margin -333.6%, net loss $47.2M, operating cash flow −$48.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.8M | +4% | +47% |
| Operating profit | −$46.0M | — | — |
| Net earnings | −$47.2M | — | — |
| Operating cash flow | −$48.3M | — | — |
What changed
Revenue was $13.8M in Q4 2025, up 47% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $46.0M, an operating margin of -333.6%. Total costs grew 31% against revenue growth of 47%. The fastest-growing cost line was Research & development (+36%). The quarter ended with a net loss of $47.2M, narrower than the previous quarter's $48.2M loss.
Operating cash flow was −$48.3M. Non-cash charges added back $6K of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items used $4.0M.
Questions
What was Gossamer Bio's revenue in the fourth quarter 2025?
Gossamer Bio (GOSS) reported revenue of $13.8M for the fourth quarter 2025 (Q4 2025), +47% from a year earlier and +4% from the quarter before.
Was Gossamer Bio profitable in the fourth quarter 2025?
Operating loss was $46.0M (-333.6% of revenue) and net loss $47.2M.
Source: Gossamer Bio 10-K on SEC EDGAR.